Lung Cancer Treatment Market to Grow at 14.21% CAGR as Precision Oncology Changes Care Economics

Key Highlights

The lung cancer treatment market was valued at USD 23.02 billion in 2025 and is forecast to reach nearly USD 58.35 billion by 2032, growing at a 14.21% CAGR from 2026 to 2032.

North America held the largest share in 2025, supported by incidence, aging demographics, treatment technology and reimbursement policies.

Targeted therapy led treatment revenue in 2025 because it targets cancer cells and molecules with higher efficacy and lower toxicity than traditional chemotherapy.

Hospitals led end-use demand in 2025 as cancer care shifts toward diagnostics, genetic testing, surgery, radiation, chemotherapy and immunotherapy.

MMR does not name a fastest-growing segment; it says immunotherapy has gained demand and popularity, driving significant segment growth.

Why This Matters Now

Lung Cancer Treatment Market care is moving from broad treatment to precision treatment, changing economics for hospitals, drugmakers, payers and regulators. Providers must fund diagnostics and specialist capacity, while pharma and biotech companies must defend targeted and immunotherapy pipelines.

MMR cites lung cancer as the second most common cancer and leading cause of cancer death, with 238,340 estimated U.S. diagnoses and 127,070 deaths in 2023. That burden converts into demand for earlier diagnosis, treatment selection and access to advanced oncology services.

Market Overview

The market covers non-small cell lung cancer and small cell lung cancer across targeted therapy, immunotherapy, chemotherapy, radiation therapy and surgery. MMR values it at USD 23.02 billion in 2025 and projects nearly USD 58.35 billion by 2032 at a 14.21% CAGR.

What changed is the shift from standard chemotherapy toward targeted therapies, immunotherapies and combination regimens. The report links growth to rising patient numbers, new treatment methods, government support, collaboration and faster adoption of advanced therapies.

Restraints remain material. High treatment cost, regulatory delays, safety concerns, resistance to new treatments and limited insurance coverage in developing markets restrict access. The market is splitting between precision-ready systems and regions still reliant on older treatment models.

Request To Free Sample of This Strategic Report ➤ https://www.maximizemarketresearch.com/request-sample/219976/ 

Key Trends Driving Growth

Targeted therapy is leading because lung cancer treatment is becoming molecular. MMR cites Osimertinib and Crizotinib for NSCLC, where therapies aimed at genetic alterations are more effective and less toxic than traditional chemotherapy. Diagnostics and drug selection now sit at the center of commercial growth.

Immunotherapy is gaining demand as treatment protocols expand. The report cites pembrolizumab and nivolumab approvals as milestones that widened treatment options. For payers, this raises budget exposure; for hospitals, it demands coordinated planning.

Combination therapy is rising as a response to resistance. Chemotherapy with immunotherapy, and targeted therapy with radiation, are being explored to improve efficacy and reduce resistance. Multidisciplinary oncology teams benefit first.

Digital health is entering oncology delivery. MMR cites telemedicine, digital pathology and remote patient monitoring as tools that can improve rural access and patient outcomes. AI is also becoming a competitive layer, with European providers using it for efficiency and Bristol Myers Squibb investing in AI, computational biology and digital health.

Segment Insights

Dominant Segment — Cancer Type: Non-small cell lung cancer held the largest market share in 2025. Its lead is tied to the availability and effectiveness of NSCLC treatments, especially targeted therapies aimed at genetic alterations.

 Dominant Segment — Treatment Type: Targeted therapy held the largest revenue share in 2025. Its advantage is specificity: it attacks cancer-linked molecules while reducing toxicity compared with traditional chemotherapy.

Fastest-Growing Segment: MMR does not name a fastest-growing segment. It states that immunotherapy has gained demand and popularity in recent years, leading to significant growth.

Dominant Segment — End User: Hospitals held the largest end-user share in 2025 and are expected to grow through 2032. Their advantage is infrastructure: diagnostic tools, genetic testing and specialist teams.

Regional Growth Story

North America led the market in 2025. MMR links that position to lung cancer incidence, aging population, technological advancement and reimbursement policies. For the United States, growth depends on disease burden and reimbursement capacity.

Europe ranked second. Growth is tied to rising patient numbers, advanced healthcare systems, stronger infrastructure, R&D investment and public funding. Germany and the United Kingdom are identified as major European countries with the largest patient numbers, making them central markets for oncology capacity and early detection.

The European Commission’s European Cancer Information System is cited as supporting coordination of treatment processes. For regulators, data infrastructure is becoming part of cancer policy. For companies, this raises expectations around evidence and outcomes.

Asia Pacific is included in the scope, with China, Japan, India and South Korea among covered countries. Rising cases and limited access to advanced therapies create opportunities where affordability and infrastructure will decide adoption.

Competitive Landscape

Competition is shifting toward precision assets, immunotherapy reach and technology-enabled development. AstraZeneca is described as research-driven and investing heavily in new medicines, drugs and treatment methods. Sustained R&D depth now defends oncology position.

Bristol Myers Squibb’s investment in AI, computational biology and digital health points to treatment efficiency and personalization. Pfizer is cited for innovation, technological development and research, including gene editing for genetically passed diseases. The common thread is a shift from products toward platforms connecting science, data and delivery.

Request To Free Sample of This Strategic Report ➤ https://www.maximizemarketresearch.com/request-sample/219976/ 

Recent Developments

Novartis agreed in May 2023 to acquire Mariana Oncology, a preclinical-stage biotechnology company developing radioligand therapies for cancers with high unmet need. The move signals interest in modalities where conventional options remain limited.

 Bristol Myers Squibb acquired Mirati in August 2023 to bring KRAZATI, described as a best-in-class KRASG12C inhibitor approved by the U.S. FDA for advanced NSCLC. The deal shows that biomarker-led assets are strategic targets, with reimbursement likely tied to defined patient groups.

Merck & Co., Inc. announced in January 2023 that the U.S. FDA approved KEYTRUDA as a single agent for adjuvant treatment after surgical resection and platinum-based chemotherapy in adult stage IB, II or IIIA NSCLC. The approval signals immunotherapy’s move into earlier care and demand for coordinated post-surgery pathways.

Strategic Implications

For healthcare providers, infrastructure is the priority. Hospitals that combine genetic testing, advanced diagnostics, multidisciplinary teams and remote monitoring will capture more growth. Providers without that capacity risk becoming referral feeders.

For pharma and biotech, the market rewards assets tied to biomarkers, combination protocols and resistant disease. Acquisitions in radioligand therapy and KRAS inhibition show that differentiated mechanisms are deal currency.

For payers and regulators, access will determine impact. Faster FDA and EMA pathways can accelerate availability, but high costs and uneven coverage can slow uptake. Value-based care will depend on measurable patient benefit under budget pressure.

Future Outlook

The market is moving toward precision, earlier intervention and connected oncology delivery. Growth will come from targeted therapy, immunotherapy, diagnostics, AI-enabled development, digital health and hospital-based integrated care. Future leaders will convert science into accessible, reimbursed, measurable outcomes; laggards will remain constrained by price, access and infrastructure.

Analyst Perspective

“Lung cancer treatment is becoming a precision-led market where growth depends on diagnostics, molecular targeting, hospital capability and reimbursement readiness,” said Komal Patil, Analyst at Maximize Market Research. “The next phase will favor companies and providers that can connect innovation with patient access and clinical outcomes.”

Explore Relevant Reports:

Global Medical Equipment Maintenance Market ➤

https://www.maximizemarketresearch.com/market-report/global-medical-equipment-maintenance-market/20669/

Surgical Suture Market ➤

https://www.maximizemarketresearch.com/market-report/global-surgical-suture-market/16660/

GI Stool Testing Market ➤

https://www.maximizemarketresearch.com/market-report/gi-stool-testing-market/220795/

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com